Anticancer and Antimicrobial Screening of Novel Pyrazolo[2,3-c]pyridopyridazine Analogues: Synthesis, Spectral Characterization, Molecular Docking and Dynamics Studies

Abstract

A major threat in cancer management is the development of drug resistance and gene mutations. Serine threonine kinases like DYRK1A pathway are potential targets for cancer therapies. In this work, a new series of seven pyrazolo[2,3-c]pyridopyridazine analogs were synthesized and characterized by spectroscopic methods. Three compounds were evaluated for in-vitro anticancer activity following 60 cell lines protocol of NCI, USA and for antimicrobial activity against Gram-negative and Gram-positive bacteria. All the compounds exhibited moderate to good antibacterial activity, while compounds 4a, 4b and 4d showed moderate responses against leukemia, ovarian cancer, and prostate cancer cell lines in anti-proliferative studies.